Feature | March 31, 2014

Terumo to Purchase Arterial Remodeling Technologies’ Bioresorbable Stent Technology

Terumo Corp. Arterial Remodeling Technologies Bioresorbable Coronary Stent

March 31, 2014 — Privately held Arterial Remodeling Technologies (ART) signed a structured buyout agreement with Terumo Corp. Under the agreement, ART and Terumo Corp. will collaborate in the development of a drug eluting bioresorbable scaffold or stent, intended for use in the treatment of coronary artery disease. ART Security Holders will retain full ownership of the ART bioresorbable scaffold technology for all other indications. Terumo Corp. will make staged R&D investments in ART, and ART has granted an exclusive option to Terumo Corp. to purchase ART at any time prior to the initiation of clinical trials.


ART’s advanced bioresorbable scaffold is designed to provide a transient effective scaffold that dismantles and relinquishes its primary mechanical scaffolding function after three months, which is commonly recognized by experts as the requisite length of time necessary to allow the healing process to stabilize the artery following trauma generated by angioplasty, and to avoid recoil and constrictive remodeling.


ART wishes to thank its investors: Bpifrance, Idinvest Partners, Turenne Capital Partners, Matignon Investissement & Gestion, Vesale Partners and Amundi Asset Management.


ART also wishes to thank three esteemed institutions for their invaluable support: the Cleveland Clinic; the French national research institute, CNRS, Montpellier, France; and Descartes University, Paris.


ART’s bioresborbable stent is not approved for investigational use or sale in the United States.


For more information: www.art-stent.com, www.terumomedical.com


Related Content

European interventional cardiology market, drug-eluting stents, Abbott Laboratories, Boston Scientific, Medtronic

Boston Scientific's Eluvia drug-eluting vascular stent system. Image courtesy of Boston Scientific.

Feature | Stents| July 31, 2015
According to a new report on the Europe market for interventional cardiology by iData Research, drug-eluting stents...
Boston Scientific, fully absorbable scaffold, FAST study, resorbable
Feature | Stents Bioresorbable| July 20, 2015
Boston Scientific has initiated a study of the company's first fully resorbable drug-eluting scaffold system. The Fully...
InspireMD, CGuard, PARADIGM study, EuroPCR 2015, Musialek

Image courtesy of InspireMD

News | Embolic Protection Devices| June 23, 2015
InspireMD Inc. announced that its CGuard embolic prevention system reported positive results in the PARADIGM study at...
Stentys, Xposition S, CE Mark, EuroPCR
News | Stents| June 18, 2015
Stentys announced in April that it received CE Marking for its new Self-Apposing stent system ahead of plan. The...
News | Stents Carotid| June 17, 2015
Karam Moon, M.D., winner of the DePuy Synthes Cerebrovascular Section Resident/Fellow Award, presented his research,...
Fantom, REVA Medical, FANTOM II trial, ACC

Fantom image courtesy of REVA Medical Inc.

News | June 05, 2015
REVA Medical Inc. announced the initiation of patient enrollment in the FANTOM II clinical trial of its Fantom...
electronic stents, bioresorbable electronic stent, BES

An illustration of the bioresorbable electronic stent developed in the Korean study. It uses a magnesium stent which doubles as a wireless transmission antenna, flexible microelectronic sensors for blood flow and temperature, and a polylactic acid polymer coating with embedded drug-filled nanospheres that release the drug only when stimulated by heat or light. Image from ACS Nano.

Feature | May 28, 2015 | Dave Fornell
With the recent innovation of flexible microelectronic sensor circuits that can be made from bioresorbable materials,...
ART, PBS, pure bioresorbable scaffold, CE Mark
Feature | May 26, 2015
Privately-held company Arterial Remodeling Technologies (ART) announced CE Mark clearance for its next-generation drug-...
Boston Scientific, Synergy, EVOLVE I, EVOLVE II, EuroPCR 2015, results
News | May 22, 2015
Boston Scientific reported positive, long-term data from the EVOLVE Trial of the Synergy everolimus-eluting...
Amaranth Medical, Fortitude BRS, MEND-II, RENASCENT, EuroPCR 2015

Image courtesy of Amaranth Medical

News | May 21, 2015
Amaranth Medical announced plans to report clinical results from the company's ongoing trial of its second-generation...
Overlay Init